PRAECIS

26 May 2005

Dear Hospital Pharmacy:

IMPORTANT INFORMATION ABOUT PLENAXIS® AVAILABILITY

This letter is being sent to provide important information regarding the continued commercial use and availability of Plenaxis® (abarelix for injectable suspension). Our records indicate that your hospital pharmacy has enrolled in the Plenaxis® User Safety (PLUS) Program, and that you are therefore authorized to dispense Plenaxis® to physicians who are also enrolled in the PLUS Program.

As announced on May 20, 2005, as part of a strategic restructuring of its organization and operations, PRAECIS PHARMACEUTICALS INCORPORATED ("PRAECIS" or the "Company") has voluntarily discontinued promotional activities relating to Plenaxis® in the United States and the sale of Plenaxis® for patients not currently on therapy. This difficult decision was prompted solely by commercial considerations, and was not prompted in any way by safety, efficacy or other regulatory issues.

PRAECIS is working with the United States Food and Drug Administration to continue to make Plenaxis® available to those patients in the United States who are now receiving the drug and to minimize disruptions in these patients' therapy. Accordingly, until further notice, your pharmacy may continue to dispense Plenaxis® to physicians enrolled in the PLUS Program, if those physicians are treating patients currently receiving Plenaxis®. If necessary, your pharmacy may order additional Plenaxis® kits for these patients through your established ordering channels. Your pharmacy must continue to abide by all of the terms of the Hospital Pharmacy's Acceptance of Responsibilities that was signed in connection with your pharmacy's enrollment in the PLUS Program, including the requirement to verify (for each kit of Plenaxis® that you dispense) that the prescribing physician is enrolled in the PLUS Program. Confirmation of PLUS enrollment can be obtained by calling (866) PLENAXIS.

You should not dispense product in your inventory to physicians to initiate new patients on Plenaxis® therapy. Any unused kits of Plenaxis® should be returned to the distributor from whom you made your purchase for a refund.

PRAECIS will inform your pharmacy of any new or unexpected information regarding the use of Plenaxis® that may become available in a timely fashion. If you have any questions regarding the important information contained in this letter, please contact PRAECIS Medical Information at (781) 795-4303 or (866) PLENAXIS.

PRAECIS is committed to ensuring that patients currently receiving Plenaxis® continue to receive the benefit of treatment for as long as appropriate. The decision to cease making Plenaxis® available to new patients at this time was an extremely difficult one and one that was made after carefully weighing all alternatives. PRAECIS appreciates your understanding and will continue to work with you during this transition period.

Sincerely yours,

Marc B. Garnick, M.D.
Chief Medical and Regulatory Officer
PRAECIS PHARMACEUTICALS INCORPORATED

PL41 05/05

PRAECIS
PHARMACEUTICALS
INCORPORATED

830 Winter Street
Waltham, MA 02451-1420

Tel 781 795 4100
www.praecis.com